Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [31] High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Serizawa, Masakuni
    Uehara, Hisanori
    Tanimura, Keiko
    Okuma, Yusuke
    Fukuda, Akito
    Watanabe, Satoshi
    Nishioka, Naoya
    Takeda, Takayuki
    Chihara, Yusuke
    Takemoto, Shinnosuke
    Harada, Taishi
    Hiranuma, Osamu
    Shirai, Yukina
    Shukuya, Takehito
    Nishiyama, Akihiro
    Goto, Yasuhiro
    Shiotsu, Shinsuke
    Kunimasa, Kei
    Morimoto, Kenji
    Katayama, Yuki
    Suda, Kenichi
    Mitsudomi, Tetsuya
    Yano, Seiji
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Takayama, Koichi
    CANCER SCIENCE, 2023, 114 (02) : 606 - 618
  • [32] Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer
    Tian, Wentao
    Niu, Lishui
    Zhou, Rongrong
    Wang, Ziqi
    Ning, Jiaoyang
    Lu, Ruoyu
    Shi, Yin
    Tan, Zhaohua
    CANCER MEDICINE, 2024, 13 (16):
  • [33] Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
    Steendam, Christi M. J.
    Veerman, G. D. Marijn
    Pruis, Melinda A.
    Atmodimedjo, Peggy
    Paats, Marthe S.
    van der Leest, Cor
    von der Thusen, Jan H.
    Yick, David C. Y.
    Oomen-de Hoop, Esther
    Koolen, Stijn L. W.
    Dinjens, Winand N. M.
    van Schaik, Ron H. N.
    Mathijssen, Ron H. J.
    Aerts, Joachim G. J. V.
    Dubbink, Hendrikus Jan
    Dingemans, Anne-Marie C.
    CANCERS, 2020, 12 (11) : 1 - 17
  • [34] Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Liang, Huan-Wei
    Liu, Yang
    Pan, Xin-Bin
    AGING-US, 2024, 16 (01): : 857 - 871
  • [35] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
  • [36] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [37] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
  • [38] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [39] A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
    Isla, Dolores
    Felip, Enriqueta
    Garrido, Pilar
    Insa, Amelia
    Majem, Margarita
    Remon, Jordi
    Trigo, Jose M.
    de Castro, Javier
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (01) : 283 - 291
  • [40] Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
    Chevallier, Mathieu
    Tsantoulis, Petros
    Addeo, Alfredo
    Friedlaender, Alex
    CANCER GENOMICS & PROTEOMICS, 2020, 17 (05) : 597 - 603
12345